Intermediate-stage hepatocellular carcinoma patients with a high HBV-DNA load may benefit from postoperative anti-hepatitis B virus therapy

Liver resection may be beneficial in intermediate-stage hepatocellular carcinoma (HCC), though the benefit of postoperative anti-hepatitis B virus (HBV) therapy in these patients remains unclear. In this study, we sought to evaluate the efficacy of postoperative anti-HBV for intermediate-stage HCC p...

Descripción completa

Detalles Bibliográficos
Autores principales: Rui, Shaozhen, Yan, Jun, Zhang, Hui, Wang, Zhengfeng, Zhou, Wence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
7100
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627838/
https://www.ncbi.nlm.nih.gov/pubmed/28746212
http://dx.doi.org/10.1097/MD.0000000000007608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627838/
https://www.ncbi.nlm.nih.gov/pubmed/28746212
http://dx.doi.org/10.1097/MD.0000000000007608

Ejemplares similares